Foghorn Drops FHD-909 Development After Phase 1, Shifts Focus To Proprietary Pipeline
Foghorn Therapeutics (FHTX) will halt development of FHD-909 after Phase 1 trial results showed insufficient efficacy, ending collaboration with Eli Lilly. The company will focus on its proprietary pipeline and reduce workforce by 40%. Wedbush downgraded FHTX to Neutral, cutting its price target to $2. FHTX shares closed at $2.02, down 30.82%.
How this was made
The 30-second read
Why it matters
The abrupt program termination and partnership end represent a setback for the company's pipeline and likely trigger further sell‑offs in the biotech sector.
Market read
The news provides fresh, material information on a listed biotech, prompting immediate price action and potential re‑evaluation of the company's valuation.
What to watch
Potential cash‑runway extension to 2029 and cost cuts may give the company time to redeploy capital.
Background
Foghorn Therapeutics (FHTX) is a Nasdaq‑listed biotech focused on chromatin‑regulatory targets. The company had previously partnered with Eli Lilly on a SMARCA2 degrader.
Ticker impact
Foghorn Therapeutics announced it will halt development of its FHD-909 program after Phase 1 data and ended its partnership with Eli Lilly, causing a 30% share drop.
downward pressure as investors price in the loss of a lead candidate and partnership revenue.
The news is a primary disclosure of a material program halt for a listed biotech, already reflected in a sharp share decline.
Market effects
May weigh on other chromatin‑targeting biotech peers as the synthetic‑lethality approach faces efficacy concerns.
Limited to US biotech sector; no broader regional effect.
Low global impact beyond niche biotech investors.
Counterpoint
If the EP300/CBP degraders show early promise, the stock could rebound on future data releases.
Key entities
- companyFoghorn Therapeutics Inc.
Biotech firm developing chromatin‑regulatory therapeutics.
- companyEli Lilly and Co.
Pharma partner in the halted SMARCA2 degrader program.